Academic Journal
Q1Drug Safety
About Drug Safety
Drug Safety is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 1.452 and H-index of 151.
Coverage: 1990-2026. Research categories: Pharmacology (Q1); Pharmacology (medical) (Q1); Toxicology (Q1).
Verified field sources
- Journal Impact Factor: 5.9 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Pharmacovigilance and Adverse Drug Reactions; Drug-Induced Adverse Reactions; Pharmaceutical Practices and Patient Outcomes; Pharmaceutical studies and practices; Pharmaceutical Economics and Policy; Drug-Induced Hepatotoxicity and Protection.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,990.00 USD; 3,890.00 EUR; 3,090.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Consumer Views on the Role of the Natural Health Products (NHPs) Industry in Pharmacovigilance for NHPs: A Qualitative Study in New Zealand
Xin Yi Lim, Shane Scahill, Sanyogita Ram, Joanne Barnes et al.
2026-10-02 · DOI: 10.1007/s40264-026-01732-zDrug Brand Switching: A Regulatory Perspective
Ping Siu Kee, Paul K. L. Chin, Michael Tatley, Rhiannon Braund et al.
2026-10-01 · DOI: 10.1007/s40264-026-01712-3The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBase
Annette Rudolph, Monica Tarapues, Oskar Gauffin, Qun-Ying Yue et al.
2026-10-01 · DOI: 10.1007/s40264-026-01711-4Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis
Thibault Viguier, Julien Bezin, Alex Hlavaty, Charles Khouri et al.
2026-09-22 · DOI: 10.1007/s40264-026-01731-0The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update
Jürgen Beckmann, Marco Tuccori, Priya Bahri, Francesco Salvo et al.
2026-09-20 · DOI: 10.1007/s40264-026-01717-yA Text-Mining Algorithm for Identifying Drug Pairs Potentially Involved in Prescribing Cascades: Development and Internal Validation Within the Prescribing Inappropriateness Assessment (PINA) Digital Tool
Massimo Carollo, Anna Forti, Salvatore Crisafulli, Luca L’Abbate et al.
2026-09-19 · DOI: 10.1007/s40264-026-01733-yInterpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation
Yoshihiro Uesawa
2026-09-17 · DOI: 10.1007/s40264-026-01726-xAuthors’ Reply to John Diaz-Decaro’s comment on: “Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness”
Agustín Ciapponi, Jamile Ballivian, Mabel Berrueta, Juan M. Sambade et al.
2026-09-17 · DOI: 10.1007/s40264-026-01727-wComment on “Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness”
John Diaz-Decaro
2026-09-17 · DOI: 10.1007/s40264-026-01728-9The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy
Manfred Hauben, Rave Harpaz, Robert Weber
2026-09-17 · DOI: 10.1007/s40264-026-01707-0Non-genetic Risk Factors for Allopurinol-Induced Severe Cutaneous Adverse Reaction (SCAR): A Systematic Review
Wei Leik Ng, Prawira Oka, Karleen Chong, Siok Fuang Liong et al.
2026-09-15 · DOI: 10.1007/s40264-026-01729-8Sodium Glucose Co-Transporter 2 Inhibitors and Ventricular Arrhythmias in Patients with Type 2 Diabetes: A Systematic Review of Observational Studies
Wang-Choi Tang, Wanning Wang, Antonios Douros, Oriana Hoi Yun Yu et al.
2026-09-06 · DOI: 10.1007/s40264-026-01715-0Development and Validation of a Two-Stage NLP System Combining Rule-Based Extraction and LLM-Based Classification for Deprescribing Recommendations in Discharge Summaries
Kenji Fujita, Marion Matheson, Bhavya Valecha, Sarah N. Hilmer et al.
2026-09-03 · DOI: 10.1007/s40264-026-01716-z25th ISoP Global Meeting “Ecosystems of Trust: Pharmacovigilance for a Healthier World” 22–25 September 2026 San José, Costa Rica
2026-10 · DOI: 10.1007/s40264-026-01704-3Challenges and Insights from the Mepolizumab Pregnancy Exposure Study
Keele E. Wurst, Michael Schatz, Subramanya Kumar, Megan Delgado et al.
2026-09-03 · DOI: 10.1007/s40264-026-01724-zISoP MENA Chapter: Strategic Development and Future Directions Following a Decade of Strengthening Pharmacovigilance in the Middle East and North Africa
Hadir Rostom, Mohamed A. Elhawary, Mayada Alkhakany, Manal M. Younus et al.
2026-10 · DOI: 10.1007/s40264-026-01723-0Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study
You Wang, Alexandra S. Storaci, G. Caleb Alexander, Jason B. Gibbons et al.
2026-09-02 · DOI: 10.1007/s40264-026-01722-1Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials
Ameet Sarpatwari, Frazer A. Tessema, Mayookha Mitra-Majumdar, Su Been Lee et al.
2026-09-02 · DOI: 10.1007/s40264-026-01721-2Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem
Tarek A. Hammad, Justine Rochon, Kate Gofman, Gianluca Trifirò et al.
2026-08-28 · DOI: 10.1007/s40264-026-01719-wArtificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV
G. Niklas Norén, Julie Durand, Vijay Kara, Elizabeth MacEntee Pileggi et al.
2026-08-26 · DOI: 10.1007/s40264-026-01708-zReviews
Community Reviews
Version History
September 25, 2026 at 7:29 am
September 25, 2026